All In Biotech

Drug Trial Radar · NCT05374564

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Aug 16, 2022

Primary completion

Nov 14, 2024

Study completion Nov 14, 2024

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
May 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. This study is designed to evaluate a novel use for 18F-Flutemetamol in cardiac amyloidosis.

Conditions

  • Cardiomyopathies, Primary

Interventions

  • (18F)FlutemetamolDrug

    18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
  2. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
  3. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
  4. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
  5. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamolTime frame: 6 months
  6. Determine if treatment with tafamidis reduces 18F-flutemetamol cardiac PET imaging markersTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.